Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
If youve been prescribed a GLP-1, understanding costs and insurance coverage can help you navigate affordability concerns
Order the 64mg pen for established, high-volume studies where the titration curve is already mapped and total peptide cost per mg matters more than format flexibility
No retatrutide has not yet received marketing authorisation from the MHRA or EMA and is not available through NHS or private prescribing channels in the UK
In one study, more than a quarter of participants in the 12-mg dose group lost 30% or more of their baseline weight, showcasing the drugs potential for dramatic weight reduction
GLP-1 receptor agonists were initially developed to improve glycemic control in type 2 diabetes by enhancing insulin secretion and inhibiting glucagon release, with additional effects on appetite regulation and gastric emptying later recognized as clinically relevant (Chao et al